Solutions To a Pressing Clinical Need.

High infection rates and a better understanding of underlying health impact increase the demand for screening for STI organisms including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Herpes Simplex Virus 1 & 2 (HSV1 & HSV2)*, and Human Papillomavirus (HPV)* in targeted populations around the world.

This demand comes at a time when laboratories are challenged by the pressure to contain healthcare costs, a shortage of trained personnel and expectations to deliver more, and higher quality results.

BD has developed solutions that fulfill your screening and diagnostic needs with :

  • A clinically relevant menu
  • A range of molecular systems
  • Superior laboratory productivity and efficiency with Lean & "Six sigma" methodologies

Learn more about...

[bullet] New Amplified Molecular Tests Launched to Help Improve Diagnosis and Treatment of Herpes Patients »

[thumbnail image] BD Viper™ with XTR™ technology »

STI Archive»

Products & Services

1 - BD Viper™ XTR System »

2 - BD ProbeTec™ ET System »

3 - BD ProbeTec™ ET Reagents »

4- BD Affirm™ VP III Microbial Identification System »